A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastatic Breast Cancer

PrintE-mail
Title A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastatic Breast Cancer
Contact CU
Principal Investigator Ellis Levine, MD
Study Number 212212
Phase2
Summary To determine if the addition of bortezomib to fulvestrant improves median progression free survival (PFS) compared with fulvestrant alone in postmenopausal and premenopausal women with ER-positive locally advanced inoperable or metastatic breast cancer who have disease that is resistant to aromatase inhibitor therapy (arms A vs. B)
For more information about the clinical study go to Clinicaltrial.Gov